Document Detail

The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
MedLine Citation:
PMID:  22376147     Owner:  NLM     Status:  MEDLINE    
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, and AF is associated with relatively higher all-cause mortality in both men and women. However, there are limited treatment options for AF. Statins are hypothesized to have a benefit against arrhythmias in addition to well-established secondary prevention benefit for atherosclerotic coronary artery disease, yet the data are inconsistent
WHAT THIS STUDY ADDS: Statin therapy was significantly associated with a decreased risk of incidence or recurrence of AF. The benefit of statin therapy seemed more markedly in secondary prevention than primary prevention. These results provided some evidence for the benefit of statins beyond their lipid-lowering activity
AIMS: The use of statins has been suggested to protect against atrial fibrillation (AF) in some clinical observational and experimental studies but has remained inadequately explored. This study was designed to examine whether statins can reduce the risk of AF.
METHODS: Meta-analysis of randomized, controlled trials with use of statins on incidence or recurrence of AF was performed.
RESULTS: Twenty studies with 23,577 patients were included in the analysis. Seven studies investigated the use of statins in patients with AF, 11 studies investigated the primary prevention of statins in patients without AF, and two studies investigated mixed populations of patients. The incidence or recurrence of AF occurred in 1543 patients. Overall, statin therapy was significantly associated with a decreased risk of AF compared with control (odds ratio 0.49, 95% confidence interval 0.37-0.65; P < 0.00001). A beneficial effect was found in the atorvastatin subgroup and the simvastatin subgroup, but not in the pravastatin subgroup or the rosuvastatin subgroup. The benefit of statin therapy appeared to be more pronounced in secondary prevention (odds ratio 0.34, 95% confidence interval 0.18-0.64; P < 0.0008) than in primary prevention (odds ratio 0.54, 95% confidence interval 0.40-0.74; P < 0.0001).
CONCLUSIONS: Statin therapy was significantly associated with a decreased risk of incidence or recurrence of AF. Heterogeneity was explained by differences in statin types, patient populations and surgery types. The benefit of statin therapy seemed more pronounced in secondary than in primary prevention.
Wen-tong Fang; Hong-Jian Li; Haibo Zhang; Su Jiang
Related Documents :
12225477 - Subcutaneous chest ports via the internal jugular vein. a retrospective study of 117 on...
15673207 - Intrathecal baclofen therapy over 10 years.
11586197 - Early removal of the catheter after laparoscopic radical prostatectomy.
10379447 - Reduced rates of catheter-associated infection by use of a new silver-impregnated centr...
21082587 - Secure tracks device improves functional recovery and pain after total knee arthroplast...
22180157 - No need to search for the source of haematogenous arthroplasty infections.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  74     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-09     Completed Date:  2013-03-06     Revised Date:  2013-11-07    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  744-56     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Department of Pharmacy, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Fibrillation / epidemiology,  physiopathology,  prevention & control*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Primary Prevention / methods
Randomized Controlled Trials as Topic
Recurrence / prevention & control
Secondary Prevention / methods
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Individual and parental factors related to meaning in life among Hungarian minority adolescents from...
Next Document:  The Role of Obesity in the Development of Polycystic Ovary Syndrome.